Vancomycin individual dosing regimens via Bayesian simulation: a 5-year retrospective study on preterm and term...

Area of Science:

• Pharmacology
• Neonatal Medicine
• Drug Development

Background:

• Vancomycin dosing in neonates presents challenges due to significant pharmacokinetic variability.
• Developmental changes in neonates impact drug absorption, distribution, metabolism, and excretion.
• Optimizing vancomycin therapy is crucial to ensure efficacy and minimize toxicity in this vulnerable population.

Purpose of the Study:

• To characterize vancomycin pharmacokinetics in a large cohort of preterm and term neonates.
• To develop individualized vancomycin dosing regimens tailored to neonatal characteristics.
• To provide evidence-based recommendations for safe and effective vancomycin use in neonates.

Main Methods:

• A retrospective study analyzed data from 255 neonates over 5 years.
• An allometric one-compartment model was used to describe vancomycin concentrations.
• Population pharmacokinetic parameters, including clearance (CL) and volume of distribution (V), were estimated and influenced by covariates.

Main Results:

• Body weight and postmenstrual age significantly influenced vancomycin clearance and volume of distribution.
• Vancomycin clearance reached 50% of adult values around 43.6 weeks postmenstrual age.
• Renal maturation, indicated by creatinine production rate, was a significant covariate in the pharmacokinetic model.
• Bayesian-guided individualized dosing regimens were successfully developed and evaluated.

Conclusions:

• Individualized vancomycin dosing is essential for neonates, particularly preterm infants.
• Avoiding vancomycin overdosage is critical in very premature infants (postmenstrual age < 25 weeks).
• Personalized dosing strategies considering body weight, postmenstrual age, and renal function are necessary to optimize vancomycin efficacy and safety.